{"id":"W4297821517","doi":"10.1016/j.annonc.2022.07.1882","title":"1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"EMD Serono; Genentech; CTI Biopharma; Ipsen; Mirati Therapeutics; Institute for Clinical Evaluative Sciences; Calithera Biosciences; TG Therapeutics; Novocure; Eisai; Jazz Pharmaceuticals; Puma Biotechnology; Regeneron Pharmaceuticals; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Celgene; Boston Biomedical; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Nausea; Clinical endpoint; Internal medicine; Prostate cancer; Adverse effect; Cancer; Phases of clinical research; Oncology; Urology; Chemotherapy; Immunotherapy; Clinical trial; Pembrolizumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008043445,0.001423932,0.001871665,0.0003992767,0.0003453108,0.001072343,0.000827244,0.001068977,0.005574422],"category_scores_gemma":[0.0006109553,0.0005425189,0.001381323,0.0003660799,0.0008245002,0.0007375976,0.0003468333,0.003441005,0.001535409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026044,"about_ca_system_score_gemma":0.001357039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002082331,"about_ca_topic_score_gemma":0.005403929,"domain_scores_codex":[0.999698,0.0001180717,0.00001096086,0.00005373723,0.00003116373,0.00008805911],"domain_scores_gemma":[0.9996802,0.00004053361,0.00004342418,0.00002101755,0.00001758087,0.0001973365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7413632,0.0362536,0.00439457,0.001021214,0.002348773,0.0003427871,0.0002997437,0.003607111,0.04697187,0.0008330239,0.01045162,0.1521124],"study_design_scores_gemma":[0.7239473,0.2496905,0.01057861,0.00005363157,0.0008082902,0.0005267744,0.00009374614,0.00216445,0.00479753,0.0004416422,0.006841662,0.00005587064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865137,0.002933,0.0005818185,0.0009741703,0.0003733862,0.001305246,0.002455236,0.0002434211,0.004620002],"genre_scores_gemma":[0.9846159,0.002463418,0.001509626,0.0008961852,0.0001801721,0.0008470132,0.003545323,0.0000549236,0.005887474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005574422,"threshold_uncertainty_score":0.01864833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09520743144419953,"score_gpt":0.4310226322050076,"score_spread":0.3358152007608081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}